Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 52

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 52
---
 was signed by both MIRA and SKNY on March 19, 2025.

On March 14, 2025, each of SKNY and MIRA granted Moore access to its data room.

On March 17, 2025, MIRA and Moore provided SKNY with a list of diligence questions related to SKNY’s pipeline, clinical development plans, the competitive landscape, regulatory and commercial considerations. Additionally, Moore provided MIRA with a list of diligence questions related to SKNY’s pipeline, clinical development plans, the competitive landscape, regulatory and commercial considerations

On March 21, 2025, MIRA provided Moore with a detailed forecast of MIRA’s research and development and general administrative expenses through 2027, proforma financials, historical R&D spending analysis, estimated drug prices, market share information, and royalty information, as prepared by MIRA’s Chief Financial Officer and controller. MIRA’s Chief Scientific Advisor provided Moore a presentation, including targeted diseases and a roadmap for all clinical trials and timelines. MIRA’s Chief Executive Officer also had input to all deliverables.

On March 23, 2025, Moore provided MIRA with follow up questions related to diligence. MIRA promptly responded with the requested information.

On March 26, MIRA’s Chief Financial
Officer provided responses to the questions asked by Moore.

On April 8, 2025, Moore provided SKNY with follow up questions related to diligence. SKNY promptly responded with the requested information.

On April 9, 2025, Moore provided the parties a preliminary valuation of SKNY.

On April 10, 2025, Moore provided the parties a preliminary valuation of MIRA.

On April 21, 2025, Moore provided a preliminary oral discussion of its valuation results with the management teams of MIRA and SKNY.

On April 22, 2025, Moore provided SKNY’s and MIRA’s management with an initial fairness opinion for the Exchange Ratio and valuation reports of SKNY and MIRA.

On April 30, 2025, MIRA’s board of directors held a meeting to discuss the approval of the Merger Agreement and Exchange Ratio. Moore presented MIRA’s board of directors with an analysis of its determination of MIRA’s and SKNY’s valuations. MIRA’s and SKNY’s management provided a discussion regarding the benefits of the Merger. MIRA’s legal counsel provided a discussion on the potential conflicts of interest involved in the Merger. Following several discussions and questions